江中药业(600750) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue rose by 16.72% to CNY 537,286,600.72 year-on-year[10] - Net profit attributable to shareholders increased by 9.50% to CNY 127,051,494.49 compared to the same period last year[10] - Total operating revenue for Q1 2019 was $537.29 million, an increase of 16.73% compared to $460.33 million in Q1 2018[49] - Net profit for Q1 2019 reached $130.42 million, representing a 12.00% increase from $116.07 million in Q1 2018[51] - The company's operating revenue for Q1 2019 was CNY 358,714,259.57, a decrease of 2.4% compared to CNY 367,595,695.75 in Q1 2018[55] - The net profit for Q1 2019 reached CNY 118,980,074.50, representing an increase of 17.3% from CNY 101,419,341.73 in Q1 2018[57] Assets and Liabilities - Total assets increased by 14.66% to CNY 4,376,403,909.88 compared to the end of the previous year[10] - Total liabilities rose to ¥645,819,660.87 from ¥563,530,666.77, which is an increase of about 14.6%[39] - Current assets increased to ¥2,709,626,600.93 from ¥2,293,747,071.49, representing a growth of approximately 18.1% year-over-year[32] - The total assets of the company amounted to 3,816,971,960.48 RMB, with current assets totaling 2,293,747,071.49 RMB[70] - Total liabilities amounted to ¥563,530,666.77, with current liabilities at ¥453,731,008.40 and non-current liabilities at ¥109,799,658.37[71] Cash Flow - Cash flow from operating activities decreased by 21.70% to CNY 83,115,380.42 compared to the previous year[10] - The net cash flow from operating activities for the current period is RMB 83.12 million, a decrease of RMB 23.04 million, reflecting a decline of 21.70% due to increased tax payments compared to the previous year[24] - The cash flow from operating activities for Q1 2019 was CNY 83,115,380.42, a decrease of 21.7% compared to CNY 106,155,123.61 in Q1 2018[62] - Total cash inflow from operating activities was 313,863,527.14 RMB, while cash outflow was 251,735,294.02 RMB, resulting in a positive cash flow from operations[64] Research and Development - The research and development expenses for the current period amount to RMB 10.50 million, an increase of RMB 6.44 million, representing a growth rate of 158.78% due to increased R&D investment and expanded consolidation scope[24] - Research and development expenses increased to $10.50 million in Q1 2019, up 159.99% from $4.06 million in Q1 2018[49] - Research and development expenses increased to CNY 7,346,560.15 in Q1 2019, up 81.5% from CNY 4,055,944.18 in Q1 2018[55] Acquisitions and Investments - The company completed the acquisition of Sanhai Pharmaceutical and Jisheng Pharmaceutical, expanding its operational scope[14] - The company completed the acquisition of 51% equity in Sanghai Pharmaceutical and Jisheng Pharmaceutical, which has been included in the consolidation scope since February 2019[25] - The balance of goodwill at the end of the period is RMB 15.84 million, resulting from the difference between the consideration paid for the acquisition of subsidiaries and the fair value of identifiable net assets[21] Equity and Shareholders - The company reported a weighted average return on equity of 3.83%, a decrease of 0.07 percentage points from the previous year[10] - The balance of minority shareholders' equity at the end of the period is RMB 350.24 million, an increase of RMB 350.09 million, primarily due to the recognition of minority interests from the acquisition of Sanghai Pharmaceutical and Jisheng Pharmaceutical[24] - Total equity attributable to shareholders reached ¥3,253,296,386.76, with retained earnings of ¥2,182,409,430.23[71] Regional Performance - Revenue from the South China region grew by 30.50% compared to the previous year[16] - Revenue from the prescription drug category saw a significant increase of 330.99% due to the acquisition of subsidiaries[12] Financial Standards and Reporting - The company executed new financial instrument standards starting January 1, 2019, adjusting the classification of certain financial assets[75] - The company also adopted new revenue standards from January 1, 2019, reporting advance receipts from sales in "contract liabilities"[75] - The audit report is not applicable for the current period[82]